Scarica l'app Stockscreener
10.55
6.57%
0.65
Dopo l'orario di chiusura:
10.78
0.23
+2.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$9.90
Aprire:
$9.92
Volume 24 ore:
11.13M
Relative Volume:
2.20
Capitalizzazione di mercato:
$3.26B
Reddito:
$571.16M
Utile/perdita netta:
$-38.10M
Rapporto P/E:
-86.12
EPS:
-0.1225
Flusso di cassa netto:
$-48.91M
1 W Prestazione:
+6.57%
1M Prestazione:
+12.00%
6M Prestazione:
+70.99%
1 anno Prestazione:
+3.94%
Intervallo 1D:
$9.78
$11.00
Intervallo di 1 settimana:
$9.725
$11.00
Portata 52W:
$5.51
$11.00
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
10.55 | 3.05B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Aggiornamento | Needham | Hold → Buy |
| 2025-07-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Amicus Therapeutics (FOLD) Stock News, Forecasts and Analyst Outlook on Dec. 14, 2025: What’s Driving the Rally? - ts2.tech
Amicus Therapeutics Stock Dips Amid Market Volatility - StocksToTrade
Why Amicus Therapeutics (FOLD) Is Up 6.6% After Bullish Analyst Upgrades On Earnings Outlook - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Hits New 12-Month HighStill a Buy? - MarketBeat
Amicus Therapeutics Capitalizes on Strategic Expansion and Surges in Stock Price - StocksToTrade
Amicus Therapeutics’ Stock Benefits from Financial Resilience Despite Marginal Decline - timothysykes.com
Analyst Upgrade: Is Amicus Therapeutics Inc stock a smart buy before Fed meetingJuly 2025 Fed Impact & Low Risk Entry Point Guides - moha.gov.vn
Amicus Therapeutics (FOLD) Soars to 52-Week High on ‘Strong Buy’ Reco - MSN
683 Capital Management LLC Acquires 685,000 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics stock hits 52-week high at 10.61 USD By Investing.com - Investing.com Nigeria
Amicus Therapeutics stock hits 52-week high at 10.61 USD - Investing.com
Wall Street Analysts See a 60.61% Upside in Amicus Therapeutics (FOLD): Can the Stock Really Move This High? - Finviz
Redmile Group LLC Sells 8,344,671 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Osterweis Capital Management Inc. Sells 573,805 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Jump Financial LLC Raises Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
How Amicus Therapeutics Inc. (FOLD) Affects Rotational Strategy Timing - news.stocktradersdaily.com
3,235,538 Shares in Amicus Therapeutics, Inc. $FOLD Bought by Norges Bank - MarketBeat
Amicus Therapeutics, Inc. $FOLD Shares Sold by JPMorgan Chase & Co. - MarketBeat
Can Galafold continue to drive Amicus' top line in 2026? - MSN
Amicus Therapeutics, Inc. $FOLD Shares Sold by Prudential Financial Inc. - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock - Finviz
Can Galafold Continue to Drive Amicus' Top Line in 2026? - Yahoo Finance
Schroder Investment Management Group Purchases 649,177 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
What is the fair value estimate for Amicus Therapeutics Inc. (AM6) stock in 2025Quarterly Portfolio Summary & Free Real-Time Volume Trigger Notifications - Newser
Amicus Therapeutics (NASDAQ:FOLD) CEO Sells 14,587 Shares - MarketBeat
Is Amicus Therapeutics Inc. (AM6) stock nearing a technical breakout2025 Analyst Calls & Consistent Profit Trade Alerts - Newser
BMY Gains on News of Continuation of Alzheimer's Disease Study - Finviz
Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
How Amicus Therapeutics Inc. (AM6) stock performs in volatility spikes2025 Trading Recap & Reliable Breakout Stock Forecasts - Newser
Pompe Disease Treatment Market is expected to reach US$ 4.06 - openPR.com
Amicus Therapeutics CEO Sells Shares - TradingView
What analysts say about Amicus Therapeutics Inc stockStock Valuation Metrics & We Spotted the Next Tesla – See Inside - earlytimes.in
Will Amicus Therapeutics Inc. (AM6) stock benefit from mergersLong Setup & Safe Capital Growth Stock Tips - Newser
Capital Fund Management S.A. Has $4.37 Million Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Will Amicus Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Highlights & Reliable Entry Point Trade Alerts - Newser
Why Amicus Therapeutics Inc. (AM6) stock could break out in 2025Recession Risk & Daily Profit Maximizing Tips - Newser
Amicus Therapeutics, Inc. $FOLD Stock Position Raised by Virtus Investment Advisers LLC - MarketBeat
Creative Planning Purchases 180,652 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Advantage Alpha Capital Partners LP Makes New Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation as Shares Gain 11% Over Past Month - Yahoo Finance
How Strong Galafold and Pombiliti Sales Helped Amicus Therapeutics (FOLD) Surpass Expectations and Shift Its Outlook - Yahoo Finance
Intech Investment Management LLC Sells 47,907 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc. $FOLD Stock Holdings Increased by Jefferies Financial Group Inc. - MarketBeat
Geode Capital Management LLC Sells 57,278 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Envestnet Asset Management Inc. Has $368,000 Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
David Michael Clark Sells 25,643 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Insider Selling: Amicus Therapeutics (NASDAQ:FOLD) CEO Sells 14,587 Shares of Stock - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Acquires 95,565 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics chief people officer sells $258,932 in stock By Investing.com - Investing.com UK
Insider Sell Alert: David Clark Sells 25,643 Shares of Amicus Th - GuruFocus
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):